Elicio Therapeutics, Inc.
ELTX
$11.68
-$0.50-4.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.75% | 2.10% | -41.24% | -31.51% | -47.46% |
| Total Depreciation and Amortization | -4.24% | -1.04% | 1.05% | -13.63% | 0.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -49.08% | -20.52% | 5,423.83% | 179.43% | 598.34% |
| Change in Net Operating Assets | -187.02% | 11.51% | 187.57% | 397.38% | 7,045.61% |
| Cash from Operations | 0.31% | -1.78% | 2.89% | 4.40% | -13.38% |
| Capital Expenditure | 81.61% | -7.14% | 48.28% | -77.55% | -31.82% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -100.00% | -91.18% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 80.95% | -15.38% | 46.43% | -625.00% | -162.50% |
| Total Debt Issued | -49.99% | -49.99% | -- | -- | 97.27% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.93% | -25.81% | 31.51% | 23.95% | 224.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -27,550.00% | -102.54% | -102.54% |
| Cash from Financing | -13.29% | -34.70% | 189.34% | 5.12% | 9.60% |
| Foreign Exchange rate Adjustments | 118.18% | 3,520.00% | 530.77% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -104.33% | -161.98% | 202.38% | 124.42% | -11.82% |